- Recommendation ID
- HST5/1
- Question
NICE encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of eliglustat and enzyme replacement therapy for treating type 1 Gaucher disease.
- Any explanatory notes
(if applicable) N/A
Source guidance details
- Comes from guidance
- Eliglustat for treating type 1 Gaucher disease
- Number
- HST5
- Date issued
- June 2017
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | Yes |
| Last Reviewed | 30/06/2017 |